Literature DB >> 22174112

Idiopathic pulmonary fibrosis: increased survival with "gastroesophageal reflux therapy": fact or fallacy?

Ganesh Raghu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22174112     DOI： 10.1164/rccm.201110-1842ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  10 in total

Review 1.  The Importance of Tyrosine Phosphorylation Control of Cellular Signaling Pathways in Respiratory Disease: pY and pY Not.

Authors:  Yael Aschner; Gregory P Downey
Journal:  Am J Respir Cell Mol Biol       Date:  2018-11       Impact factor: 6.914

Review 2.  New approaches to modulating idiopathic pulmonary fibrosis.

Authors:  Richard H Gomer
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

3.  Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.

Authors:  Joyce S Lee; Harold R Collard; Kevin J Anstrom; Fernando J Martinez; Imre Noth; Rhonda S Roberts; Eric Yow; Ganesh Raghu
Journal:  Lancet Respir Med       Date:  2013-06-14       Impact factor: 30.700

4.  The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis.

Authors:  Joyce S Lee
Journal:  Clin Pulm Med       Date:  2014-03-01

5.  Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model.

Authors:  Christina Nelson; Jameisha Lee; Kang Ko; Andrew G Sikora; Mark D Bonnen; Perenlei Enkhbaatar; Yohannes T Ghebre
Journal:  Front Pharmacol       Date:  2017-01-26       Impact factor: 5.810

6.  Altered epigenetic features in circulating nucleosomes in idiopathic pulmonary fibrosis.

Authors:  J Guiot; I Struman; V Chavez; M Henket; M Herzog; K Scoubeau; N Hardat; B Bondue; J L Corhay; C Moermans; R Louis
Journal:  Clin Epigenetics       Date:  2017-08-15       Impact factor: 6.551

7.  A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis.

Authors:  Akio Takezaki; Shin-Ichi Tsukumo; Yasuhiro Setoguchi; Julie G Ledford; Hisatsugu Goto; Kazuyoshi Hosomichi; Hisanori Uehara; Yasuhiko Nishioka; Koji Yasutomo
Journal:  J Exp Med       Date:  2019-10-10       Impact factor: 14.307

8.  Patients' and healthcare professionals' perspectives on the idiopathic pulmonary fibrosis care journey: a qualitative study.

Authors:  Anouk Delameillieure; Fabienne Dobbels; Sarah Vandekerkhof; Wim A Wuyts
Journal:  BMC Pulm Med       Date:  2021-03-18       Impact factor: 3.317

9.  Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis.

Authors:  Yohannes T Ghebremariam; John P Cooke; William Gerhart; Carol Griego; Jeremy B Brower; Melanie Doyle-Eisele; Benjamin C Moeller; Qingtao Zhou; Lawrence Ho; Joao de Andrade; Ganesh Raghu; Leif Peterson; Andreana Rivera; Glenn D Rosen
Journal:  J Transl Med       Date:  2015-08-01       Impact factor: 5.531

Review 10.  Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations.

Authors:  Yutaro Nakamura; Takafumi Suda
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2016-09-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.